French Validation of a Severity Scale in REM Sleep Behavior Disorder (SEV-TCSP) — SEV-TCSP  

REM Sleep Behavior Disorder Clinical Trial

Official title: French Validation of a Severity Scale in REM Sleep Behavior Disorder

Status Recruiting

Clinical Trial Summary

REM (Rapid Eye Movements) Sleep Behavior Disorder (RBD) is a parasomnia characterized by episodes of elaborate or violent motor activity during dreams, which can lead to injury and sleep disruption in patient and / or his/her spouse. This is due to the loss of the normal muscle atonia during REM Sleep. RBD is often associated to neurodegenerative diseases, and may even precede them for several years as an early marker. Currently, there is no scale or tool for assessing the severity of RBD. Nevertheless, it is crucial to have a tool of severity when one wants to study the natural evolution of this disorder, as well as the possible effect of a drug in the context of a clinical trial. A Severity Scale of RBD has recently been proposed within the International RBD Study Group and an international validation study in several languages is being considered.

The main objective of this study is to validate a new scale of severity of the REM sleep behavior disorder (RBD Severity Scale or RBDSS) and to characterize its metrological properties, in particular its concurrent validity, internal consistency and reproducibility

Clinical Trial Description

Research involving the human person, non-interventional, category 3

80 patients with RBD of any etiology (eg Idiopathic RBD, RBD associated with Parkinson's Disease, Multiple System Atrophy, Narcolepsy etc.) and their bedpartners (if available) will be include in 5 French centers (Clermont-Ferrand, Paris, Nantes, Montpellier et Lyon) Patients, and their bedpartners (if available), will be seen 2 times at 1 week intervals.

For the patients Visit 1 (Day 0): duration : 60 minutes

• Information to patient and collection of non-opposition

• Collection of socio-demographic data: age, sex, level of education

• Clinical data collection: duration of RBD, duration and severity of the concomitant disease:, medical and surgical history

• Assessment of cognitive functions: Mini Mental State Examination

• Verification of inclusion / exclusion criteria

• Ongoing treatments and calculation of Levodopa Equivalent Daily Dose (LEDD) for PD patients.

• RBD severity scale for Patient (RBDSS-PT) + Global Clinical Impression-Severity Scale

Visit 2 (J7) : duration : 20 minutes

• Ongoing treatments

• RBDSS PT + Global Clinical Impression-Severity Scale (CGI-S-PT)

• Patient will be given a Weekly Severity Agenda for 4 weeks plus a copy of the RBSSS-PT + Global Clinical Impression-Severity Scale

At home, patients will fill :

D8 à D36 :

• Weekly Severity Agenda (wRBDQ) for 4 weeks

D36 :

• RBDSS-PT + Clinical Global Impression-Severity These documents will be mailed back in a pre-payed envelop. For the Bed Partners Visit 1 (D0- baseline): duration: 30 minutes

• Information of and collection of non opposition

• Collection of socio-demographic data: age, sex, level of education

• Assessment of cognitive functions: Mini Mental State Examination

• Verification of inclusion / exclusion criteria

• Ongoing Treatments

• RBD severity scale of the bed partner (RBDSS BP)+ Global Clinical Impression-Severity Scale

Visit 2 (D7- retest) : duration : 20 minutes

• Ongoing treatments

• RBDSS-BP + Clinical Overall Impression Severity Scale

• Patient will be given a Weekly Joint Severity Agenda to be completed together with the patient, (wRBDQ) for 4 weeks, plus a copy of the RBDSS-BP + CGI-S-BP

At home: bedpartners will fill:

D8 à D36 :

• Weekly Severity Agenda for 4 weeks, in common with patient

D36 :

• RBDSS-BP + Impression Global Clinique-Severity scale These documents will be mailed back in a pre-payed envelop. ;

Related Conditions & MeSH terms

• Disease
• Mental Disorders
• REM Sleep Behavior Disorder

• NCT number: NCT04071899
• Study type: Observational
• Source: University Hospital, Clermont-Ferrand
• Contact: Lise Laclautre
• Phone: +334.73.751.195
• Email: drci@chu-clermontferrand.fr
• Status: Recruiting
• Start date: May 24, 2019
• Completion date: September 24, 2020